AGN 192836 is a potent and selective α2 adrenergic agonist with EC 50 s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively. In Vitro Binding assays demonstrates that AGN 192836 is 1200-fold selective for the α2A-receptor relative to the α1-receptor, 50-fold selective for the α2A-receptor relative to the α2B-receptor, and 10-fold selective for the α2Areceptor relative to the α2C-receptor. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo AGN 192836 is equally efficacious when compared to brimonidine for the reduction of intraocular pressure upon topical administration to the rabbit and more efficacious than brimonidine for the reduction of blood pressure upon intravenous administration to monkey . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:α adrenergic receptor